


Amendment of the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (currently amended) A process for extending the lifespan of a metazoan or metazoan cells comprising administering to said metazoan or metazoan cells a composition comprising a C(sub)60 compound represented by the following structure: ~~having x pairs of adjacent carbon atoms bonded to two carbons of said C₆₀ compound wherein said adjacent carbon atom is further bonded to two groups of a general formula -COOH and -R,~~




wherein C is directly bonded to two adjacent carbons of C(sub)60 and R is independently selected from the group consisting of -COOH and -H, and wherein x is at least 1.

2. (original) The process of Claim 1 where x is 4.
3. (currently amended) The process of Claim 1 ~~claim 2~~ wherein said composition comprises said C(sub)60 compound, its pharmaceutically acceptable salts and pharmaceutically accepted esters, and a pharmaceutically acceptable carrier, present in said composition in a therapeutically effective amount.
4. (original) The process of Claim 1 wherein x is 3.
5. (original) The process of Claim 4 wherein said C(sub)60 compound is C(sub)3 tris malonic acid C₆₀.

6. (original) The process of Claim 1 wherein said C(sub)60 compound is administered intravenously, intramuscularly, subcutaneously or orally.
7. (original) The process of Claim 6 wherein said C(sub)60 compound is administered intravenously, intramuscularly or subcutaneously in an amount of at least 0.1 mg/kg.
8. (original) The process of Claim 7 wherein said C(sub)60 compound is administered intravenously, intramuscularly or subcutaneously in an amount of about 3 mg/kg.
9. (original) The process of Claim 6 wherein said C(sub)60 compound is administered orally in an amount of at least 0.1 mg/kg.
10. (original) The process of Claim 6 wherein said C(sub)60 compound is administered orally in an amount of about 15 mg/kg.
11. (original) The process of Claim 7 wherein said C(sub)60 compound is administered daily.
12. (original) The process of Claim 9 wherein said C(sub)60 compound is administered daily.
13. (original) The process of Claim 1 wherein said metazoan is a vertebrate.
14. (original) The process of Claim 1 wherein said metazoan is a mammal.
15. (original) The process of Claim 1 wherein said metazoan is a human.
16. (currently amended) A process for extending a metazoan's lifespan comprising regularly administering a non-metallic superoxide dismutase-mimetic to said metazoan wherein said metazoan's lifespan is extended.
17. (canceled)
18. (currently amended) The process of Claim 16 ~~claim 17~~ wherein said non-metallic superoxide dismutase-mimetic comprises a carboxyfullerene.

19. (currently amended) The process of Claim 18 wherein said carboxyfullerene comprises a C(sub)60 compound ~~having x pairs of adjacent carbon atoms bonded to two carbons of said C₆₀ compound wherein said adjacent carbon atom is further bonded to two groups of a general formula -COOH and -R, wherein R is independently selected from the group consisting of -COOH and -H, and wherein x is at least 1.~~ represented by the following structure:



wherein C is directly bonded to two adjacent carbons of C(sub)60 and R is independently selected from the group consisting of -COOH and -H, and wherein x is at least 1.

20. (currently amended) The process of Claim 19 wherein x is ~~about~~ 4.
21. (original) The process of Claim 19 wherein x is 3.
22. (original) The process of Claim 21 wherein said C(sub)60 compound is C(sub)3 tris malonic acid C₆₀.


23. (original) The process of Claim 18 wherein said carboxyfullerene is administered intravenously, intramuscularly, subcutaneously or orally.

24. (original) The process of Claim 23 wherein said carboxyfullerene is administered intravenously, intramuscularly or subcutaneously in an amount of at least 0.1 mg/kg.

25. (original) The process of Claim 24 wherein said carboxyfullerene is administered intravenously, intramuscularly or subcutaneously in an amount of about 3 mg/kg.

26. (original) The process of Claim 18 wherein said carboxyfullerene is administered orally in an amount at least 0.1 mg/kg.

27. (original) The process of Claim 26 wherein said carboxyfullerene is administered orally in an amount of about 15 mg/kg.
28. (original) The process of Claim 24 wherein said compound is administered daily.
29. (original) The process of Claim 26 wherein said compound is administered daily.
30. (original) The process of Claim 16 wherein said metazoan is a human.
31. (canceled)
32. (canceled)
- 33-55. (canceled).
56. (currently amended) A process for extending the lifespan of a human comprising administering to said human a composition comprising a C(sub)60 compound ~~having x pairs of adjacent carbon atoms bonded to two carbons of said C₆₀ compound wherein said adjacent carbon atom is further bonded to two groups of a general formula -COOH and -R, wherein R is independently selected from the group consisting of -COOH and -H, and wherein x is at least 1~~ represented by the following structure:



wherein C is directly bonded to two adjacent carbons of C(sub)60 and R is independently selected from the group consisting of -COOH and -H, and wherein x is at least 1.

57. (currently amended) The process of Claim 56 where x is ~~about~~ 4.
58. (original) The process of Claim 56 wherein said composition comprises said C(sub)60 compound, its pharmaceutically acceptable salts and pharmaceutically accepted esters,

and a pharmaceutically acceptable carrier, present in said composition in a therapeutically effective amount.

59. (original) The process of Claim 56 wherein x is 3.

60. (original) The process of Claim 59 wherein said C(sub)60 compound is C(sub)3 tris malonic acid C₆₀.

61. (original) The process of Claim 56 wherein said C(sub)60 compound is administered intravenously, intramuscularly, subcutaneously or orally.

62. (original) The process of Claim 61 wherein said C(sub)60 compound is administered intravenously, intramuscularly or subcutaneously in an amount of at least 0.1 mg/kg.

63. (original) The process of Claim 62 wherein said C(sub)60 compound is administered intravenously, intramuscularly or subcutaneously in an amount of about 3 mg/kg.

64. (original) The process of Claim 61 wherein said C(sub)60 compound is administered orally in an amount of at least 0.1 mg/kg.

65. (original) The process of Claim 64 wherein said C(sub)60 compound is administered orally in an amount of about 15 mg/kg.

66. (original) The process of Claim 62 wherein said C(sub)60 compound is administered daily.

67. (original) The process of claim 64 wherein said C(sub)60 compound is administered daily.

68. (canceled)

69. (canceled)